Avacta Group (AVCT) H2 2025 TU earnings summary

Executive summary

• Achieved significant progress in developing the pre|CISION® tumor-activated oncology platform, with two programs advancing toward clinical development in 2026.

• Raised £22.5m in equity and realized over £15m from the sale of non-core diagnostics businesses to fund R&D and extend cash runway into Q3 2026.

• Expanded intellectual property portfolio, including advances in sustained release and dual payload delivery mechanisms.

Financial highlights

• Unaudited cash and cash equivalents at year-end 2025 were £16.9m, supporting operations into Q3 2026.

• Equity raise of £22.5m and disposal of non-core diagnostics businesses generated over £15m.

Outlook and guidance

• Multiple data updates expected in 2026 for both salivary gland and triple negative breast cancer cohorts.

• FAP-Exd (AVA6103) clinical testing to begin in Q1 2026, with preliminary data anticipated in H2 2026.

• Continued engagement with potential partners for both lead programs as survival data matures.